B cell lineage based immunogen design with humanized animals

Patent metadata

Field	Value
Publication number	US-9963501-B2
Application number	US-201414174563-A
Country	US
Kind code	B2
Filing date	Feb 6, 2014
Priority date	Feb 6, 2013
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.

First claim

We claim:

1. A method for screening for a broad spectrum antibody against an antigen of interest from a pathogen, which is HIV, influenza or hepatitis C, comprising:
(a) administering a first immunogen derived from the antigen of interest to a mouse from a mouse line comprising in its germline:
(i) a restricted immunoglobulin heavy chain locus comprising a single human unrearranged V H gene segment, which is a human V H 1-69 gene segment or polymorphic variant thereof, one or more human D H gene segments, and one or more human J H gene segments operably linked to a heavy chain constant region nucleic acid sequence,
(ii) a genetically modified immunoglobulin light chain locus comprising one or more human V K gene segments and one or more human J K gene segments, wherein the V K and the J K gene segments are operably linked to a light chain constant region nucleic acid sequence, and wherein the first immunogen comprises a plurality of epitopes;

(b) allowing the mouse to mount an immune response against the first immunogen, wherein the immune response comprises generation of non-human B cells that express human immunoglobulin heavy chain (IgH) VDJ and human immunoglobulin light chain (IgL) VJ sequences;
(c) isolating clonally related B cells from the mouse that express a B cell receptor (BCR) that specifically binds a first epitope of the first immunogen;
(d) obtaining IgH VDJ and IgL VJ amino acid sequences expressed by the B cell receptor (BCR) of the clonally related B cells;
(e) deducing from the IgH VDJ and IgL VJ sequences unmutated B cell receptor (BCR) VDJ and VJ amino acid sequences; and one or more intermediate ancestor B cell receptor (BCR) VDJ and VJ amino acid sequences expressed by B cells at an intermediate stage of differentiation;
(f) providing a plurality of second immunogens comprising second epitopes distinct from the first epitope that bind with enhanced affinity to the unmutated B cell receptor (BCR) or the intermediate ancestor B cell receptor (BCR) relative to the first immunogen;
(g) serially administering to another mouse of the line second immunogens selected from the plurality of the second immunogens in (f), the serial administration starting with a second immunogen to the unmutated BCR and following with second immunogens to intermediate BCRs successively more distant phylogenically from the unmutated BCR; and
(h) determining whether the immune response from the mouse of (g) includes a broad spectrum antibody, which binds a plurality of the second epitopes.

2. The method of claim 1 , wherein the first and second immunogens of steps (a) and (g) are administered as a liposomal complex.

3. The method of claim 1 , wherein the antigen of interest is, or is derived from, an infectious agent or a pathogen, and the broad spectrum antibody is a broadly neutralizing antibody against the infectious agent or the pathogen.

4. The method of claim 1 , wherein all, or substantially all, functional endogenous V H D H , and J H gene segments in the immunoglobulin heavy chain locus have been deleted or rendered non-functional.

5. The method of claim 4 , wherein the restricted immunoglobulin heavy chain locus comprises an endogenous Adam6a gene, Adam6b gene, or both, and the genetic modification in the heavy chain locus does not affect the expression or function of the endogenous Adam6a gene, Adam6b gene, or both.

6. The method of claim 4 , wherein the mouse comprises an ectopically present Adam6a gene, Adam6b gene, or both.

7. The method of claim 1 , wherein the heavy or light chain constant region nucleic acid sequence is a human or a rodent nucleic acid sequence.

8. The method of claim 1 , wherein the constant region nucleic acid sequence is a mouse constant region nucleic acid sequence.

9. The method of claim 1 , wherein all, or substantially all, functional endogenous V H D H , and J H gene segments in the immunoglobulin heavy chain locus have been rendered non-functional, and the human V H , D H , and J H gene segments are present on a transgene.

10. The method of claim 1 , where the human V H , D H , and J H gene segments are operably linked to an endogenous constant region nucleic acid sequence at an endogenous non-human immunoglobulin heavy chain locus.

11. The method of claim 1 , wherein the genetically modified immunoglobulin light chain locus comprises a replacement of all, or substantially all, functional V K gene segments and J K gene segments with one or more human V K gene segments and one or more human J K segments, wherein the human V K gene segments and the human J K gene segments are operably linked to a light chain constant region nucleic acid sequence.

12. The method of claim 1 , wherein the mouse comprises a replacement at the endogenous non-human immunoglobulin V K locus of all or substantially all functional endogenous V K gene segments with human V K gene segments the group consisting of selected from V K 4-1, V K 5-2, V K 7-3, V K 2-4, V K 1-5, V K 1-6, V K 3-7, V K 1-8, V K 1-9, V K 2-10, V K 3-11, V K 1-12, V K 1-13, V K 2-14, V K 3-15, V K 1-16, V K 1-17, V K 2-18, V K 2-19, V K 3-20, V K 6-21, V K 1-22, V K 1-23, V K 2-24, V K 3-25, V K 2-26, V K 1-27, V K 2-28, V K 2-29, V K 2-30, V K 3-31, V K 1-32, V K 1-33, V K 3-34, V K 1-35, V K 2-36, V K 1-37, V K 2-38, V K 1-39, V K 2-40, and a combination thereof.

13. The method of claim 1 , wherein the mouse comprises a replacement at the endogenous non-human immunoglobulin J K locus of all or substantially all functional endogenous non-human immunoglobulin J K gene segments with human J K gene segments selected from J K 1, J K 2, J K 3, J K 4, J K 5, and a combination thereof.

14. The method of claim 11 , wherein the one or more human V K and J K segments are operably linked to an endogenous light chain constant region nucleic acid sequence at an endogenous non-human locus.

Assignees

• Regeneron Pharma
• Univ Duke

Inventors

• Haynes Barton
• Kelsoe Garnett
• Lowy Israel
• Baras Aris I
• Macdonald Lynn
• Mcwhirter John
• Gurer Cagan
• Meagher Karolina A
• Murphy Andrew J
• Yancopoulos George D

Classifications

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• G01N2500/00

  Screening for compounds of potential therapeutic value · CPC title

• A01K2267/01

  Animal expressing industrially exogenous proteins · CPC title

• A01K2217/072

  maintaining or altering function, i.e. knock in · CPC title